Compumedics announces substantial growth

Compumedics (ASX:CMP), a leader in medical diagnostic technology, reported a significant increase in sales orders in the USA and Europe for the first quarter of FY25. The USA market experienced a 136% growth in orders, driven by the sleep and Somfit business sectors. In Europe, a major contract in Poland was secured, enhancing the company's market presence.

Compumedics' strategic growth outlook

Compumedics has reported a remarkable increase in sales orders, with the USA market witnessing a 136% rise, mainly in the sleep and Somfit sectors. This growth underscores the company's effective sales strategy and market penetration. In Europe, securing a major Polish customer signifies Compumedics' competitive strength. The company has re-affirmed its FY25 sales guidance, projecting over AUD 55 million in sales and an EBITDA of about AUD 5 million. Compumedics' strategic focus on expanding its sales resources and enhancing market presence in key regions aligns with its growth objectives and reflects a positive outlook for FY25.

Executive insights on sales surge

The significant growth in our USA sales orders, particularly in the sleep and Somfit sectors, is a testament to our successful market strategies. The European market expansion, highlighted by our new Polish customer, reflects our competitive edge and commitment to delivering innovative diagnostic solutions. We remain confident in achieving our FY25 sales and EBITDA targets.